US FDA considers allowing access to anonymized drug, device trial data

US regulators are proposing to make "de-identified" and "masked" study data derived from applications submitted to the Food and Drug Administration available to external experts and other interested parties for the purpose of generating new knowledge aimed at facilitating innovation in new medical products1.